TME Pharma NV (XPAR:ALTME) 3-Year EBITDA Growth Rate : 59.10% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV 3-Year EBITDA Growth Rate?

TME Pharma NV's EBITDA per Share for the six months ended in Dec. 2023 was €-0.42.

During the past 3 years, the average EBITDA Per Share Growth Rate was 59.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 45.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of TME Pharma NV was 75.70% per year. The lowest was -14.50% per year. And the median was 48.70% per year.

Competitive Comparison of TME Pharma NV's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, TME Pharma NV's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TME Pharma NV's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's 3-Year EBITDA Growth Rate falls into.

TME Pharma NV 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

TME Pharma NV (XPAR:ALTME) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

TME Pharma NV 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV (XPAR:ALTME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

0N6A:Germany

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines